Showing 7151-7160 of 7579 results for "".
- Curcumin Nanoparticles Prevent Infections in Healing Woundshttps://practicaldermatology.com/news/20140922-curcumin_nanoparticles_prevent_infections_in_healing_wounds/2459114/Curcumin nanoparticles (curc-np) inhibit in vitro growth of methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa in dose-dependent fashion, and inhibits MRSA growth and enhances wound healing in an in vivo murine wound model, new research in the journal
- The ISDS Welcomes the Dermatology Community to Jerusalemhttps://practicaldermatology.com/news/20140917-the_international_society_for_dermatologic_surgery_welcomes_the_dermatology_community_to_jerusalem/2459116/The 35th Annual International Society for Dermatologic Surgery (ISDS) Congress will be held in Jerusalem from October 22-24, 2014. The ISDS will have the newest and latest techniques dermatologic surgery, skin cancer surgery, laser surgery, hair transplantation, varicose veins, lipolysis,
- Late Stage Skin Cancers on the Rise in the UK: World Congress on Cancers of the Skinhttps://practicaldermatology.com/news/20140917-late_stage_skin_cancers_on_the_rise_in_the_uk_world_congress_on_cancers_of_the_skin/2459119/Advanced-stage skin cancers are on the rise in the UK, according to two studies presented this month at the World Congress on Cancers of the Skin in Edinburgh, Scotland. The findings highlight an urgent need to publicise self-check and early detection messages, the The Skin Cancer Foundation says.
- Solace International Issues Recall of Dermatend Original and Dermatend Ultrahttps://practicaldermatology.com/news/20140902-solace_international_issues_recall_of_dermatend_original_and_dermatend_ultra/2459134/Solace International, Inc. is voluntarily recalling all lots of Dermatend Original and Dermatend Ultra in all sizes and dosage form to the distributor/wholesaler level. A mole should be removed under the supervision of a dermatologist. Dermatend is not FDA approved, thus has not
- MELA Sciences and Columbia University Imaging Experts Columbia Team Explore Potential Next Generation MelaFind Enhancementshttps://practicaldermatology.com/news/20140902-mela_sciences_and_columbia_university_imaging_experts_columbia_team_explore_potential_next_generation_melafind_enhancements/2459135/MELA Sciences, Inc.has executed a research agreement with Columbia University in which MELA and Columbia will collaborate to explore potential next generation capabilities and features of the MelaFind system and other enhancements to the system's range and ease of use. The company will have exclu
- Lilly's Ixekizumab Superior to Etanercept and Placebo in Phase III Psoriasis Studieshttps://practicaldermatology.com/news/20140822-lillys_ixekizumab_superior_to_etanercept_and_placebo_in_phase_iii_psoriasis_studies/2459137/Eli Lilly and Company's ixekizumab was found to be statistically superior to etanercept and placebo on all skin clearance measures in pivotal, Phase III UNCOVER studies in moderate-to-severe plaque psoriasis. "These data are important for people suffer
- Dermira Completes $51 Million Financing and Expands Management Team and Board of Directorshttps://practicaldermatology.com/news/20140821-dermira_completes_51_million_financing_and_expands_management_team_and_board_of_directors/2459139/Dermira, a specialty biopharmaceutical focused on dermatology, completed a $51 million Series C financing. Existing investors Bay City Capital, New Enterprise Associates (NEA), Canaan Partners and UCB S.A. were joined by new investors Apple Tree Partners, Aisling Capital, Rock S
- Carma Laboratories Introduces New Carmex® Cold Sore Treatmenthttps://practicaldermatology.com/news/20140820-carma_laboratories_introduces_new_carmex_cold_sore_treatment/2459142/Carma Laboratories, Inc., the maker of Carmex® lip balm products, has launched the new Carmex® Cold Sore Treatment. This product features TriPLEX™ Formula advanced technology, which combines three different optical brightener and filler technologies that each provide unique appea
- Provectus Signs Memorandum of Understanding with Sinopharm-China State Institute of Pharmaceutical Industry, And Sinopharm A-Think Pharmaceutical Co., LTDhttps://practicaldermatology.com/news/20140818-provectus_signs_memorandum_of_understanding_with_sinopharm-china_state_institute_of_pharmaceutical_industry_and_sinopharm_a-think_pharmaceutical_co_lt/2459143/Negotiations on Licensing PV-10 in China Opened Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company (“Provectus”), announced today that it entered into a Memorandum of Understanding (“MOU”) with
- Editorial: Transferrable Loyalty and the State of Our Specialtyhttps://practicaldermatology.com/news/20140806-editorial_transferrable_loyalty_and_the_state_of_our_specialty/2459149/With the ongoing battle between Allergan and Valeant, it is evident that no practicing dermatologist can avoid concerns with the painful and tactical machinations. Long-term representatives have likely already changed their nametags from one company to another and are now pitching the same drugs und